Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications

ABSTRACT

The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an ileal bile acid transport inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

This application claims priority of U.S. provisional application Ser.No. 60/143,047 filed Jul. 7, 1999 and of U.S. provisional applicationSer. No. 60/113,955 filed Dec. 23, 1998.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to methods of treating cardiovasculardiseases, and specifically relates to combinations of compounds,compositions, and methods for their use in medicine, particularly in theprophylaxis and treatment of hyperlipidemic conditions such as areassociated with atherosclerosis, hypercholesterolemia, and othercoronary artery disease in mammals. More particularly, the inventionrelates to ileal bile acid transporter (IBAT) inhibiting compounds. Theinvention also relates to cholesteryl ester transfer protein (CETP)activity inhibiting compounds.

2. Description of Related Art

It is well-settled that hyperlipidemic conditions associated withelevated concentrations of total cholesterol and low-density lipoprotein(LDL) cholesterol are major risk factors for coronary heart disease andparticularly atherosclerosis. Since high levels of LDL cholesterolincrease the risk of atherosclerosis, methods for lowering plasma LDLcholesterol would be therapeutically beneficial for the treatment ofatherosclerosis and other diseases associated with accumulation of lipidin the blood vessels. These diseases include, but are not limited to,coronary heart disease, peripheral vascular disease, and stroke.

Atherosclerosis underlies most coronary artery disease (CAD), a majorcause of morbidity and mortality in modern society. High LDL cholesterol(above about 180 mg/dl) and low HDL cholesterol (below 35 mg/dl) havebeen shown to be important contributors to the development ofatherosclerosis. Other diseases or risk factors, such as peripheralvascular disease, stroke, and hypercholesterolaemia are negativelyaffected by adverse HDL/LDL ratios.

Interfering with the recirculation of bile acids from the lumen of theintestinal tract is found to reduce the levels of serum cholesterol in acausal relationship. Epidemiological data has accumulated whichindicates such reduction leads to an improvement in the disease state ofatherosclerosis. Stedronsky, in “Interaction of bile acids andcholesterol with nonsystemic agents having hypocholesterolemicproperties,” Biochimica et Biophysica Acta, 1210, 255-287 (1994)discusses the biochemistry, physiology and known active agentssurrounding bile acids and cholesterol.

Transient pathophysiologic alterations are shown to be consistent withinterruption of the enterohepatic circulation of bile acids in humanswith an inherited lack of IBAT activity, as reported by Heubi, J. E., etal. See “Primary Bile Acid Malabsorption: Defective in Vitro IlealActive Bile Acid Transport”, Gastroenterology, 83, 804-11 (1982).

In another approach to the reduction of recirculation of bile acids, theileal bile acid transport system is a putative pharmaceutical target forthe treatment of hypercholesterolemia based on an interruption of theenterohepatic circulation with specific transport inhibitors (Kramer, etal., “Intestinal Bile Acid Absorption” The Journal of BiologicalChemistry, 268 (24), 18035-46 1993).

In several individual patent applications, Hoechst Aktiengesellschaftdiscloses polymers of various naturally occurring constituents of theenterohepatic circulation system and their derivatives, including bileacid, which inhibit the physiological bile acid transport with the goalof reducing the LDL cholesterol level sufficiently to be effective aspharmaceuticals and, in particular for use as hypocholesterolemicagents. The individual Hoechst patent applications which disclose suchbile acid transport inhibiting compounds are each separately listedbelow.

R1. Canadian Patent Application No. 2,025,294.

R2. Canadian Patent Application No. 2,078,588.

R3. Canadian Patent Application No. 2,085,782.

R4. Canadian Patent Application No. 2,085,830.

R5. EP Application No. 0 379 161.

R6. EP Application No. 0 549 967.

R7. EP Application No. 0 559 064.

R8. EP Application No. 0 563 731.

Selected benzothiepines are disclosed in world patent application numberWO 93/321146 for numerous uses including fatty acid metabolism andcoronary vascular diseases.

Other selected benzothiepines are known for use as hypolipaemic andhypocholesterolaemic agents, especially for the treatment or preventionof atherosclerosis as disclosed in application No. EP 508425. A Frenchpatent application, FR 2661676 discloses additional benzothiepines foruse as hypolipaemic and hypocholesterolaemic agents. Furthermore, patentapplication no. WO 92/18462 lists other benzothiepines for use ashypolipaemic and hypocholesterolaemic agents. U.S. Pat. No. 5,994,391(Lee et al.) Each of the benzothiepine hypolipaemic andhypocholesterolaemic agents described in these individual patentapplications is limited by an amide bonded to the carbon adjacent thephenyl ring of the fused bicyclobenzothiepine ring.

Further benzothiepines useful for the treatment of hypercholesterolemiaand hyperlipidemia are disclosed in patent application no.PCT/US95/10863. More benzothiepines useful for the prophylaxis andtreatment of hypercholesterolemia and hyperlipidemia as well aspharmaceutical compositions of such benzothiepines are described inPCT/US97/04076. Still further benzothiepines and compositions thereofuseful for the prophylaxis and treatment of hypercholesterolemia andhyperlipidemia are described in U.S. Application Ser. No. 08/816,065.

In vitro bile acid transport inhibition is disclosed to correlate withhypolipidemic activity in The Wellcome Foundation Limited disclosure ofthe patent application No. WO 92/16055 for “HypolipidemicBenzothiazepine Compounds.” That publication describes a number ofhypolipidemic benzothiazepine compounds. Additional hypolipidemicbenzothiazepine compounds (particularly2,3,4,5-tetrahydrobenzo-1-thi-4-azepine compounds) are disclosed inpatent application No. WO 96/05188. A particularly usefulbenzothiazepine disclosed in WO 96/05188 is the compound of formula B-2.Further hypolipidemic benzothiazepine compounds are described in patentapplication No. WO 96/16051.

(3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-,7,8-dimethoxy-5-phenyl-1-4-benzothiazepine1,1-dioxide

Other benzothiazepine compounds useful for control of cholesterol aredescribed in PCT Patent Application No. WO 99/35135. Included in thatdescription is the compound of formula B-7.

Further IBAT inhibitor compounds include a class of naphthalenecompounds, described by T. Ichihashi et al. in J. Pharmacol. Exp. Ther.,284(1), 43-50 (1998). In this class, S-8921 (methyl1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate)is particularly useful. The structure of S-8921 is shown in formulaB-20. Further naphthalene compounds or lignin derivatives useful for thetreatment or prophylaxis of hyperlipidemia or atherosclerosis aredescribed in PCT Patent Application No. WO 94/24087.

Inhibition of cholesteryl ester transfer protein (CETP) has been shownto effectively modify plasma HDL/LDL ratios, and is expected to checkthe progress and/or formation of certain cardiovascular diseases. CETPis a plasma protein that facilitates the movement of cholesteryl estersand triglycerides between the various lipoproteins in the blood (Tall,J. Lipid Res., 34, 1255-74 (1993)). The movement of cholesteryl esterfrom HDL to LDL by CETP has the effect of lowering HDL cholesterol. Ittherefore follows that inhibition of CETP should lead to elevation ofplasma HDL cholesterol and lowering of plasma LDL cholesterol, therebyproviding a therapeutically beneficial plasma lipid profile. Evidence ofthis effect is described in McCarthy, Medicinal Res. Revs., 13, 139-59(1993). Further evidence of this effect is described in Sitori, Pharmac.Ther., 67, 443-47 (1995)). This phenomenon was first demonstrated bySwenson et al., (J. Biol. Chem., 264, 14318 (1989)) with the use of amonoclonal antibody that specifically inhibits CETP. In rabbits, theantibody caused an elevation of the plasma HDL cholesterol and adecrease in LDL cholesterol. Son et al. (Biochim. Biophys. Acta, 795,743-480 (1984)) describe proteins from human plasma that inhibit CETP.U.S. Pat. No. 5,519,001, herein incorporated by reference, issued toKushwaha et al., describes a 36 amino acid peptide derived from baboonapo C-1 that inhibits CETP activity. Cho et al. (Biochim. Biophys. Acta1391, 133-144 (1998)) describe a peptide from hog plasma that inhibitshuman CETP. Bonin et al. (J. Peptide Res., 51, 216-225 (1998)) disclosea decapeptide inhibitor of CETP. A depspeptide fungal metabolite isdisclosed as a CETP inhibitor by Hedge et al. in Bioorg. Med. Chem.Lett., 8, 1277-80 (1998).

There have been several reports of non-peptidic compounds that act asCETP inhibitors. Barrett et al. (J. Am. Chem. Soc., 188, 7863-63 (1996))describe cyclopropane-containing CETP inhibitors. Furthercyclopropane-containing CETP inhibitors are described by Kuo et al. (J.Am. Chem. Soc., 117, 10629-34 (1995)). Pietzonka et al. (Bioorg. Med.Chem. Lett., 6, 1951-54 (1996)) describe phosphonate-containing analogsof cholesteryl ester as CETP inhibitors. Coval et al. (Bioorg. Med.Chem. Lett., 5, 605-610 (1995)) describe Wiedendiol -A and -B, andrelated sesquiterpene compounds as CETP inhibitors. Lee et al. (J.Antibiotics, 49, 693-96 (1996)) describe CETP inhibitors derived from aninsect fungus. Busch et al. (Lipids, 25, 216-220, (1990)) describecholesteryl acetyl bromide as a CETP inhibitor. Morton and Zilversmit(J. Lipid Res., 35, 836-47 (1982)) describe that p-chloromercuriphenylsulfonate, p-hydroxymercuribenzoate and ethyl mercurithiosalicylateinhibit CETP. Connolly et al. (Biochem. Biophys. Res. Comm., 223, 42-47(1996)) describe other cysteine modification reagents as CETPinhibitors. Xia et al. describe 1,3,5-triazines as CETP inhibitors(Bioorg. Med. Chem. Lett., 6, 919-22 (1996)). Bisgaier et al. (Lipids,29, 811-8 (1994)) describe 4-phenyl-5-tridecyl-4H-1,2,4-triazole-thiolas a CETP inhibitor. Additional triazole CETP inhibitors are describedin U.S. patent application Ser. No. 09/153,360, herein incorporated byreference. Sikorski et al. disclosed further novel CETP inhibitors inPCT patent application No. WO 9914204.

Substituted 2-mercaptoaniline amide compounds can be used as CETPinhibitors and such therapeutic compounds are described by H. Shinkai etal. in PCT Patent Application No. WO 98/35937.

Some substituted heteroalkylamine compounds are known as CETPinhibitors. In European Patent Application No. 796846, Schmidt et al.describe 2-aryl-substituted pyridines as cholesterol ester transferprotein inhibitors useful as cardiovascular agents. One substituent atC₃ of the pyridine ring can be an hydroxyalkyl group. In European PatentApplication No. 801060, Dow and Wright describe heterocyclic derivativessubstituted with an aldehyde addition product of an alkylamine to afford1-hydroxy-1-amines. These are reported to be β3-adrenergic receptoragonists useful for treating diabetes and other disorders. In GreatBritain Patent Application No. 2305665, Fisher et al. disclose 3-agonistsecondary amino alcohol substituted pyridine derivatives useful fortreating several disorders including cholesterol levels andatherosclerotic diseases. In European Patent Application No. 818448(herein incorporated by reference), Schmidt et al. describetetrahydroquinoline derivatives as cholesterol ester transfer proteininhibitors. European Patent Application No. 818197, Schmek et al.describe pyridines with fused heterocycles as cholesterol ester transferprotein inhibitors. Brandes et al. in German Patent Application No.19627430 describe bicyclic condensed pyridine derivatives as cholesterolester transfer protein inhibitors. In PCT Patent Application No. WO9839299, Muller-Gliemann et al. describe quinoline derivatives ascholesteryl ester transfer protein inhibitors.

Polycyclic compounds that are useful as CETP inhibitors are alsodisclosed by A. Oomura et al. in Japanese Patent No. 10287662. Forexample, therapeutic compounds having the structures C-1 and C-8 wereprepared by culturing Penicillium spp.

Cycloalkylpyridines useful as CETP inhibitors are disclosed by Schmidtet al. in European Patent No. EP 818448. For example, the therapeuticcompound having the structure C-9 is disclosed as being particularlyeffective as a CETP inhibitor.

Substituted tetrahydronaphthalene compounds useful as CETP inhibitorsare described in PCT Patent Application No. WO 9914174. Specificallydescribed in that disclosure as a useful CETP inhibitor is(8S)-3-cyclopentyl-1-(4-fluorophenyl)-2-[(S)-fluoro(4-trifluoromethylphenyl)methyl]-8-hydroxy-6-spirocclobutyl-5,6,7,8-tetrahydronaphthalene.

Some 4-heteroaryl-tetrahydroquinolines useful as CETP inhibitors aredescribed in PCT Patent Application No. WO 9914215. For example, thatdisclosure describes3-(4-trifluoromethylbenzoyl)-5,6,7,8-tetrahydroquinolin-5-one as auseful CETP inhibitor.

Some combination therapies for the treatment of cardiovascular diseasehave been described in the literature. Combinations of IBAT inhibitorswith HMG CoA reductase inhibitors useful for the treatment ofcardiovascular disease are disclosed in U.S. patent application No.09/037,308.

A combination therapy of fluvastatin and niceritrol is described by J.Sasaki et al. (Id.). Those researchers conclude that the combination offluvastatin with niceritrol “at a dose of 750 mg/day dose does notappear to augment or attenuate beneficial effects of fluvastatin.”

L. Cashin-Hemphill et al. (J. Am. Med. Assoc., 264 (23), 3013-17 (1990))describe beneficial effects of a combination therapy of colestipol andniacin on coronary atherosclerosis. The described effects includenonprogression and regression in native coronary artery lesions.

A combination therapy of acipimox and simvastatin shows beneficial HDLeffects in patients having high triglyceride levels (N. Hoogerbrugge etal., J. Internal Med., 241, 151-55 (1997)).

Sitostanol ester margarine and pravastatin combination therapy isdescribed by H. Gylling et al. (J. Lipid Res., 37, 1776-85 (1996)). Thattherapy is reported to simultaneously inhibit cholesterol absorption andlower LDL cholesterol significantly in non-insulin-dependent diabeticmen.

Brown et al. (New Eng. J. Med., 323 (19), 1289-1339 (1990)) describe acombination therapy of lovastatin and colestipol which reducesatherosclerotic lesion progress on and increase lesion regressionrelative to lovastatin alone.

A combination therapy of an apoB secretion inhibitor with a CETPinhibitor was disclosed by Chang et al. in PCT Patent Application No. WO9823593.

Buch et al. (PCT Patent Application No. WO 9911263) describe acombination therapy comprising amlodipine and a statin compound fortreating subjects suffering from angina pectoris, atherosclerosis,combined hypertension and hyperlipidemia, and to treat symptoms ofcardiac arrest. Buch et al. describe in PCT Patent Application No. WO9911259 a combination therapy comprising amlodipine and atorvastatin.

Scott et al. (PCT Patent Application No. WO 9911260) describe acombination therapy comprising atorvastatin and an antihypertensiveagent.

Dettmar and Gibson (UK Patent Application No. GB 2329334 A) claim atherapeutic composition useful for reducing plasma low densitylipoprotein and cholesterol levels, wherein the composition comprises anHMG CoA reductase inhibitor and a bile complexing agent.

The above references show continuing need to find safe, effective agentsfor the prophylaxis or treatment of cardiovascular diseases.

SUMMARY OF THE INVENTION

To address the continuing need to find safe and effective agents for theprophylaxis and treatment of cardiovascular diseases, combinationtherapies of cardiovascular drugs are now reported.

Among its several embodiments, the present invention provides acombination therapy comprising the use of a first amount of an IBATinhibitor and a second amount of another cardiovascular therapeuticuseful in the prophylaxis or treatment of hyperlipidemia,atherosclerosis, or hypercholesterolemia, wherein said first and secondamounts together comprise an anti-hyperlipidemic condition effectiveamount, an anti-atherosclerotic condition effective amount, or ananti-hypercholesterolemic condition effective amount of the compounds.For example one of the many embodiments of the present invention is acombination therapy comprising therapeutic dosages of an IBAT inhibitorand a CETP inhibitor. A preferred embodiment of the present invention isa combination therapy comprising therapeutic dosages of a benzothiepineIBAT inhibitor and a CETP inhibitor.

A further embodiment of the instant invention comprises the use of anyof the cardiovascular combination therapies described herein for theprophylaxis or treatment of hypercholesterolemia, atherosclerosis, orhyperlipidemia. Therefore, in one embodiment the present inventionprovides a method for the prophylaxis or treatment of a hyperlipidemiccondition comprising administering to a patient in need thereof acombination in unit dosage form wherein the combination comprises afirst amount of an ileal bile acid transport inhibiting compound and asecond amount of a CETP inhibiting compound wherein the first amount andthe second amount together comprise an anti-hyperlipidemic conditioneffective amount of the compounds.

In another embodiment, the present invention provides a method for theprophylaxis or treatment of an atherosclerotic condition comprisingadministering to a patient in need thereof a combination in unit dosageform wherein the combination comprises a first amount of an ileal bileacid transport inhibiting compound and a second amount of a CETPinhibiting compound wherein the first amount and the second amounttogether comprise an anti-atherosclerotic condition effective amount ofthe compounds.

In still another embodiment, the present invention provides method forthe prophylaxis or treatment of hypercholesterolemia comprisingadministering to a patient in need thereof a combination in unit dosageform wherein the combination comprises a first amount of an ileal bileacid transport inhibiting compound and a second amount of a CETPinhibiting compound wherein the first amount and the second amounttogether comprise an anti-hypercholesterolemic condition effectiveamount of the compounds.

Further scope of the applicability of the present invention will becomeapparent from the detailed description provided below. However, itshould be understood that the following detailed description andexamples, while indicating preferred embodiments of the invention, aregiven by way of illustration only since various changes andmodifications within the spirit and scope of the invention will becomeapparent to those skilled in the art from this detailed description.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following detailed description is provided to aid those skilled inthe art in practicing the present invention. Even so, this detaileddescription should not be construed to unduly limit the presentinvention as modifications and variations in the embodiments discussedherein can be made by those of ordinary skill in the art withoutdeparting from the spirit or scope of the present inventive discovery.

The contents of each of the references cited herein, including thecontents of the references cited within these primary references, areherein incorporated by reference in their entirety.

a. Definitions

The following definitions are provided in order to aid the reader inunderstanding the detailed description of the present invention:

“Ileal bile acid transporter” or “IBAT” is synonymous with apical sodiumco-dependent bile acid transporter, or ASBT.

“Benzothiepine IBAT inhibitor” means an ileal bile acid transportinhibitor which comprises a therapeutic compound comprising a2,3,4,5-tetrahydro-1-benzothiepine 1,1-dioxde structure.

As used herein the term “CETP inhibitor” or “CETP inhibiting compound”means any therapeutic compound derived from chemical or biologicalsources which inhibits cholesteryl ester transfer protein activity.

“Combination therapy” means the administration of two or moretherapeutic agents to treat a hyperlipidemic condition, for exampleatherosclerosis and hypercholesterolemia. Such administrationencompasses co-administration of these therapeutic agents in asubstantially simultaneous manner, such as in a single dosage formhaving a fixed ratio of active ingredients or in multiple, separatedosage forms for each inhibitor agent. In addition, such administrationalso encompasses use of each type of therapeutic agent in a sequentialmanner. In either case, the treatment regimen will provide beneficialeffects of the drug combination in treating the hyperlipidemiccondition.

The phrase “therapeutically effective” is intended to qualify thecombined amount of inhibitors in the combination therapy. This combinedamount will achieve the goal of reducing or eliminating thehyperlipidemic condition.

“Therapeutic compound” means a compound useful in the prophylaxis ortreatment of a hyperlipidemic condition, including atherosclerosis andhypercholesterolemia.

b. Combinations

The combinations of the present invention will have a number of uses.For example, through dosage adjustment and medical monitoring, theindividual dosages of the therapeutic compounds used in the combinationsof the present invention will be lower than are typical for dosages ofthe therapeutic compounds when used in monotherapy. The dosage loweringwill provide advantages including reduction of side effects of theindividual therapeutic compounds when compared to the monotherapy. Inaddition, fewer side effects of the combination therapy compared withthe monotherapies will lead to greater patient compliance with therapyregimens.

Another use of the present invention will be in combinations havingcomplementary effects or complementary modes of action. For example,IBAT inhibitors control blood serum cholesterol levels by inhibiting thereabsorption of bile acids in the ileum. In contrast, CETP inhibitorsinhibit the movement of cholesteryl esters and triglycerides between thevarious lipoproteins in the blood.

Compounds useful in the present invention encompass a wide range oftherapeutic compounds. Some IBAT inhibitors useful in the presentinvention are disclosed in patent application no. PCT/US95/10863, hereinincorporated by reference. More IBAT inhibitors are described inPCT/US97/04076, herein incorporated by reference. Still further IBATinhibitors useful in the present invention are described in U.S.application Ser. No. 08/816,065, herein incorporated by reference. MoreIBAT inhibitor compounds useful in the present invention are describedin WO 98/40375, herein incorporated by reference. Additional IBATinhibitor compounds useful in the present invention are described inU.S. application Ser. No. 08/816,065, herein incorporated by reference.Further IBAT inhibiting compounds useful in the present invention aredisclosed in U.S. Pat. No. 5,994,391, herein incorporated by reference.IBAT inhibitors of particular interest in the present invention includethose shown in Table 1, as well as the diastereomers, enantiomers,racemates, salts, and tautomers of the IBAT inhibitors of Table 1.

TABLE 1 Compound Number Structure B-1 

B-2 

(3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7,8-dimethoxy-5-phenyl-1-4-benzothiazepine1,1-dioxide B-3 

B-4 

B-5 

B-6 

B-7 

B-8 

B-9 

B-10

B-11

B-12

B-13

B-14

B-15

R = 5000 formual weight polyethyleneglycol B-16

B-17

B-18

B-19

B-20

B-21

B-22

B-23

B-24

B-25

B-26

B-27

B-28

PEG = 3400 molecular weight polyethylene glycol polymer chain B-29

PEG = 3400 molecular weight polyethylene glycol polymer chain B-30

PEG = 3400 molecular weight polyethylene glycol polymer chain B-31

B-32

B-33

R = PEG 1000 B-34

B-35

B-36

B-37

B-38

B-39

Some individual CETP inhibitor compounds useful in the present inventionare separately described in the following individual patentapplications, each of which is individually herein incorporated byreference.

R9. U.S. patent application Ser. No. 60/101661.

R10. U.S. patent application Ser. No. 60/101711.

R11. U.S. patent application Ser. No. 60/101660.

R12. U.S. patent application Ser. No. 60/101664.

R13. U.S. patent application Ser. No. 60/101668.

R14. U.S. patent application Ser. No. 60/101662.

R15. U.S. patent application Ser. No. 60/101663.

R16. U.S. patent application Ser. No. 60/101669.

R17. U.S. patent application Ser. No. 60/101667.

R18. U.S. patent application Ser. No. 09/401,916.

R19. U.S. patent application Ser. No. 09/405,524.

R20. U.S. patent application Ser. No. 09/404,638.

R21. U.S. patent application Ser. No. 09/404,638.

R22. U.S. patent application Ser. No. 09/400,915.

R23. U.S. Pat. No. 5,932,587.

R24. U.S. Pat. No. 5,925,645.

CETP inhibitor compounds of particular interest in the present inventioninclude those shown in Table 2, as well as the diastereomers,enantiomers, racemates, salts, and tautomers of the CETP inhibitors ofTable 2.

TABLE 2 Compound Number Structure C-1

C-2

C-3

C-4

C-5

C-6

C-7

C-8

C-9

C-10

C-11

C-12

C-13

C-14

C-15

C-16

C-17

C-18

C-19

C-20

The compounds (for example, ileal bile acid transport inhibitingcompounds or CETP inhibiting compounds) useful in the present inventioncan have no asymmetric carbon atoms, or, alternatively, the usefulcompounds can have one or more asymmetric carbon atoms. When the usefulcompound have one or more asymmetric carbon atoms, they thereforeinclude racemates and stereoisomers, such as diastereomers andenantiomers, in both pure form and in admixture. Such stereoisomers canbe prepared using conventional techniques, for example by reactingenantiomeric starting materials, or by separating isomers of compoundsof the present invention.

Isomers may include geometric isomers, for example cis-isomers ortrans-isomers across a double bond. All such isomers are contemplatedamong the compounds useful in the present invention.

The compounds useful in the present invention also include tautomers.

The compounds useful in the present invention as discussed below includetheir salts, solvates and prodrugs.

Dosages, Formulations, and Routes of Administration

The compositions of the present invention can be administered for theprophylaxis or treatment of hyperlipidemic diseases or conditions by anymeans, preferably oral, that produce contact of these compounds withtheir site of action in the body, for example in the ileum, the plasma,or the liver of a mammal, e.g., a human.

For the prophylaxis or treatment of the conditions referred to above,the compounds useful in the compositions and methods of the presentinvention can be used as he compound per se. Pharmaceutically acceptablesalts are particularly suitable for medical applications because oftheir greater aqueous solubility relative to the parent compound. Suchsalts must clearly have a pharmaceutically acceptable anion or cation.Suitable pharmaceutically acceptable acid addition salts of thecompounds of the present invention when possible include those derivedfrom inorganic acids, such as hydrochloric, hydrobromic, phosphoric,metaphosphoric, nitric, sulfonic, and sulfuric acids, and organic acidssuch as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic,fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic,malic, methanesulfonic, succinic, toluenesulfonic, tartaric, andtrifluoroacetic acids. The chloride salt is particularly preferred formedical purposes. Suitable pharmaceutically acceptable base saltsinclude ammonium salts, alkali metal salts such as sodium and potassiumsalts, and alkaline earth salts such as magnesium and calcium salts.

The anions useful in the present invention are, of course, also requiredto be pharmaceutically acceptable and are also selected from the abovelist.

The compounds useful in the present invention can be presented with anacceptable carrier in the form of a pharmaceutical composition. Thecarrier must, of course, be acceptable in the sense of being compatiblewith the other ingredients of the composition and must not bedeleterious to the recipient. The carrier can be a solid or a liquid, orboth, and is preferably formulated with the compound as a unit-dosecomposition, for example, a tablet, which can contain from 0.05% to 95%by weight of the active compound. Other pharmacologically activesubstances can also be present, including other compounds of the presentinvention. The pharmaceutical compositions of the invention can beprepared by any of the well known techniques of pharmacy, consistingessentially of admixing the components.

Optionally, the combination of the present invention can comprise acomposition comprising an ileal bile acid transport inhibiting compoundand a CETP inhibiting compound. In such a composition, the ileal bileacid transport inhibiting compound and the CETP inhibiting compound canbe present in a single dosage form, for example a pill, a capsule, or aliquid which contains both of the compounds.

These compounds can be administered by any conventional means availablefor use in conjunction with pharmaceuticals, either as individualtherapeutic compounds or as a combination of therapeutic compounds.

The amount of compound which is required to achieve the desiredbiological effect will, of course, depend on a number of factors such asthe specific compound chosen, the use for which it is intended, the modeof administration, and the clinical condition of the recipient.

In general, a total daily dose of an IBAT inhibitor can be in the rangeof from about 0.01 to about 1000 mg/day, preferably from about 0.1 mg toabout 50 mg/day, more preferably from about 1 to about 10 mg/day.

For a CETP inhibitor, a daily dose of about 0.01 to about 100 mg/kg bodyweight/day, and preferably between about 0.5 to about 20 mg/kg bodyweight/day, may generally be appropriate.

The daily doses described in the preceding paragraphs for the varioustherapeutic compounds can be administered to the patient in a singledose, or in proportionate multiple subdoses. Subdoses can beadministered 2 to 6 times per day. Doses can be in sustained releaseform effective to obtain desired results.

In the case of pharmaceutically acceptable salts, the weights indicatedabove refer to the weight of the acid equivalent or the base equivalentof the therapeutic compound derived from the salt.

Oral delivery of the combinations of the present invention can includeformulations, as are well known in the art, to provide prolonged orsustained delivery of the drug to the gastrointestinal tract by anynumber of mechanisms. These include, but are not limited to, pHsensitive release from the dosage form based on the changing pH of thesmall intestine, slow erosion of a tablet or capsule, retention in thestomach based on the physical properties of the formulation, bioadhesionof the dosage form to the mucosal lining of the intestinal tract, orenzymatic release of the active drug from the dosage form. For some ofthe therapeutic compounds useful in the present invention (e.g., IBATinhibitors or CETP inhibitors), the intended effect is to extend thetime period over which the active drug molecule is delivered to the siteof action (e.g., the ileum) by manipulation of the dosage form. Thus,enteric-coated and enteric-coated controlled release formulations arewithin the scope of the present invention. Suitable enteric coatingsinclude cellulose acetate phthalate, polyvinylacetate phthalate,hydroxypropylmethylcellulose phthalate and anionic polymers ofmethacrylic acid and methacrylic acid methyl ester.

The combinations of the present invention can be delivered orally eitherin a solid, in a semi-solid, or in a liquid form. When in a liquid or ina semi-solid form, the combinations of the present invention can, forexample, be in the form of a liquid, syrup, or contained in a gelcapsule (e.g., a gel cap). In one embodiment, when an IBAT inhibitor isused in a combination of the present invention, the IBAT inhibitor canbe provided in the form of a liquid, syrup, or contained in a gelcapsule. In another embodiment, when a CETP inhibitor is used in acombination of the present invention, the CETP inhibitor can be providedin the form of a liquid, syrup, or contained in a gel capsule.

The dose of any of these therapeutic compounds can be convenientlyadministered as an infusion of from about 10 ng/kg body weight to about100 ng/kg body weight per minute. Infusion fluids suitable for thispurpose can contain, for example, from about 0.1 ng to about 10 mg,preferably from about 1 ng to about 10 mg per milliliter. Unit doses cancontain, for example, from about 1 mg to about 10 g of the compound ofthe present invention. Thus, ampoules for injection can contain, forexample, from about 1 mg to about 100 mg.

Pharmaceutical compositions according to the present invention includethose suitable for oral, rectal, topical, buccal (e.g., sublingual), andparenteral (e.g., subcutaneous, intramuscular, intradermal, orintravenous) administration, although the most suitable route in anygiven case will depend on the nature and severity of the condition beingtreated and on the nature of the particular compound which is beingused. In most cases, the preferred route of administration is oral.

Pharmaceutical compositions suitable for oral administration can bepresented in discrete units, such as capsules, cachets, lozenges, ortablets, each containing a predetermined amount of at least onetherapeutic compound useful in the present invention; as a powder orgranules; as a solution or a suspension in an aqueous or non-aqueousliquid; or as an oil-in-water or water-in-oil emulsion. As indicated,such compositions can be prepared by any suitable method of pharmacywhich includes the step of bringing into association the activecompound(s) and the carrier (which can constitute one or more accessoryingredients). In general, the compositions are prepared by uniformly andintimately admixing the active compound with a liquid or finely dividedsolid carrier, or both, and then, if necessary, shaping the product. Forexample, a table; can be prepared by compressing or molding a powder orgranules of the compound, optionally with one or more assessoryingredients. Compressed tablets can be prepared by compressing, in asuitable machine, the compound in a free-flowing form, such as a powderor granules optionally mixed with a binder, lubricant, inert diluentand/or surface active/dispersing agent(s). Molded tablets can be made bymolding, in a suitable machine, the powdered compound moistened with aninert liquid diluent.

Pharmaceutical compositions suitable for buccal (sub-lingual)administration include lozenges comprising a compound of the presentinvention in a flavored base, usually sucrose, and acacia or tragacanth,and pastilles comprising the compound in an inert base such as gelatinand glycerin or sucrose and acacia.

Pharmaceutical compositions suitable for parenteral administrationconveniently comprise sterile aqueous preparations of a compound of thepresent invention. These preparations are preferably administeredintravenously, although administration can also be effected by means ofsubcutaneous, intramuscular, or intradermal injection. Such preparationscan conveniently be prepared by admixing the compound with water andrendering the resulting solution sterile and isotonic with the blood.Injectable compositions according to the invention will generallycontain from 0.1 to 5% w/w of a compound disclosed herein.

Pharmaceutical compositions suitable for rectal administration arepreferably presented as unit-dose suppositories. These can be preparedby admixing a compound of the present invention with one or moreconventional solid carriers, for example, cocoa butter, and then shapingthe resulting mixture.

Pharmaceutical compositions suitable for topical application to the skinpreferably take the form of an ointment, cream, lotion, paste, gel,spray, aerosol, or oil. Carriers which can be used include petroleumjelly (e.g., Vaseline), lanolin, polyethylene glycols, alcohols, andcombinations of two or more thereof. The active compound is generallypresent at a concentration of from 0.1 to 50% w/w of the composition,for example, from 0.5 to 2%.

Transdermal administration is also possible. Pharmaceutical compositionssuitable for transdermal administration can be presented as discretepatches adapted to remain in intimate contact with the epidermis of therecipient for a prolonged period of time. Such patches suitably containa compound of the present invention in an optionally buffered, aqueoussolution, dissolved and/or dispersed in an adhesive, or dispersed in apolymer. A suitable concentration of the active compound is about 1% to35%, preferably about 3% to 15%. As one particular possibility, thecompound can be delivered from the patch by electrotransport oriontophoresis, for example, as described in Pharmaceutical Research,3(6), 318 (1986).

In any case, the amount of active ingredient that can be combined withcarrier materials to produce a single dosage form to be administeredwill vary depending upon the host treated and the particular mode ofadministration.

The solid dosage forms for oral administration including capsules,tablets, pills, powders, gel caps, and granules noted above comprise oneor more compounds useful in the present invention admixed with at leastone inert diluent such as sucrose, lactose, or starch. Such dosage formsmay also comprise, as in normal practice, additional substances otherthan inert diluents, e.g., lubricating agents such as magnesium stearateor solubilizing agents such as cyclodextrins. In the case of capsules,tablets, powders, granules, gel caps, and pills, the dosage forms mayalso comprise buffering agents. Tablets and pills can additionally beprepared with enteric coatings.

Liquid dosage forms for oral administration can include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, and elixirscontaining inert diluents commonly used in the art, such as water. Suchcompositions may also comprise adjuvants, such as wetting agents,emulsifying and suspending agents, and sweetening, flavoring, andperfuming agents.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions may be formulated according to the known artusing suitable dispersing or setting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectable solutionor suspension in a nontoxic parenterally acceptable diluent or solvent,for example, as a solution in 1,3-butanediol. Among the acceptablevehicles and solvents that may be employed are water, Ringer's solution,and isotonic sodium chloride solution. In addition, sterile, fixed oilsare conventionally employed as a solvent or suspending medium. For thispurpose any bland fixed oil may be employed including synthetic mono- ordiglycerides. In addition, fatty acids such as oleic acid find use inthe preparation of injectables.

Pharmaceutically acceptable carriers encompass all the foregoing and thelike.

In combination therapy, administration of two or more of the therapeuticagents useful in the present invention may take place sequentially inseparate formulations, or may be accomplished by simultaneousadministration in a single formulation or separate formulations.Administration may be accomplished by oral route, or by intravenous,intramuscular, or subcutaneous injections. The formulation may be in theform of a bolus, or in the form of aqueous or non-aqueous isotonicsterile injection solutions or suspensions. These solutions andsuspensions may be prepared from sterile powders or granules having oneor more pharmaceutically-acceptable carriers or diluents, or a bindersuch as gelatin or hydroxypropylmethyl cellulose, together with one ormore of a lubricant, preservative, surface active or dispersing agent.

For oral administration, the pharmaceutical composition may be in theform of, for example, a tablet, capsule, suspension, or liquid.Capsules, tablets, etc., can be prepared by conventional methods wellknown in the art. The pharmaceutical composition is preferably made inthe form of a dosage unit containing a particular amount of the activeingredient or ingredients. Examples of dosage units are tablets orcapsules. These may with advantage contain one or more therapeuticcompound in an amount described above. For example, in the case of anIBAT inhibitor, the dose range may be from about 0.01 mg/day to about500 mg/day or any other dose, dependent upon the specific inhibitor, asis known in the art. In the case of an bile acid sequestrant the doserange can be from about 1,000 mg/day to about 30,000 mg/day or any otherdose, dependent upon the specific bile acid sequestrant, as is known inthe art.

The active ingredients may also be administered by injection as acomposition wherein, for example, saline, dextrose, or water may be usedas a suitable carrier. A suitable daily dose of each active therapeuticcompound is one that achieves the same blood serum level as produced byoral administration as described above.

The therapeutic compounds may further be administered by any combinationof oral/oral, oral/parenteral, or parenteral/parenteral route.

Pharmaceutical compositions for use in the treatment methods of thepresent invention may be administered in oral form or by intravenousadministration. Oral administration of the combination therapy ispreferred. Dosing for oral administration may be with a regimen callingfor single daily dose, or for a single dose every other day, or formultiple, spaced doses throughout the day. The therapeutic compoundswhich make up the combination therapy may be administeredsimultaneously, either in a combined dosage form or in separate dosageforms intended for substantially simultaneous oral administration. Thetherapeutic compounds which make up the combination therapy may also beadministered sequentially, with either therapeutic compound beingadministered by a regimen calling for two-step ingestion. Thus, aregimen may call for sequential administration of the therapeuticcompounds with spaced-apart ingestion of the separate, active agents.The time period between the multiple ingestion steps may range from afew minutes to several hours, depending upon the properties of eachtherapeutic compound such as potency, solubility, bioavailability,plasma half-life and kinetic profile of the therapeutic compound, aswell as depending upon the effect of food ingestion and the age andcondition of the patient. Circadian variation of the target moleculeconcentration may also determine the optimal dose interval. Thetherapeutic compounds of the combined therapy whether administeredsimultaneously, substantially simultaneously, or sequentially, mayinvolve a regimen calling for administration of one therapeutic compoundby oral route and another therapeutic compound by intravenous route.Whether the therapeutic compounds of the combined therapy areadministered by oral or intravenous route, separately or together, eachsuch therapeutic compound will be contained in a suitable pharmaceuticalformulation of pharmaceutically-acceptable excipients, diluents or otherformulations components. Examples of suitablepharmaceutically-acceptable formulations containing the therapeuticcompounds for oral administration are given above.

Treatment Regimen

The dosage regimen to prevent, give relief from, or ameliorate a diseasecondition having hyperlipidemia as an element of the disease, e.g.,atherosclerosis, or to protect against or treat further high cholesterolplasma or blood levels with the compounds and/or compositions of thepresent invention is selected in accordance with a variety of factors.These include the type, age, weight, sex, diet, and medical condition ofthe patient, the severity of the disease, the route of administration,pharmacological considerations such as the activity, efficacy,pharmacokinetics and toxicology profiles of the particular compoundemployed, whether a drug delivery system as utilized, and whether thecompound is administered as part of a drug combination. Thus, the dosageregimen actually employed may vary widely and therefore deviate from thepreferred dosage regimen set forth above.

Initial treatment of a patient suffering from a hyperlipidemic conditioncan begin with the dosages indicated above. Treatment should generallybe continued as necessary over a period of several weeks to severalmonths or years until the hyperlipidemic disease condition has beencontrolled or eliminated. Patients undergoing treatment with thecompounds or compositions disclosed herein can be routinely monitoredby, for example, measuring serum LDL and total cholesterol levels by anyof the methods well known in the art, to determine the effectiveness ofthe combination therapy. Continuous analysis of such data permitsmodification of the treatment regimen during therapy so that optimaleffective amounts of each type of therapeutic compound are administeredat any point in time, and so that the duration of treatment can bedetermined as well. In this way, the treatment regimen/dosing schedulecan be rationally modified over the course of therapy so that the lowestamount of the therapeutic compounds which together exhibit satisfactoryeffectiveness is administered, and so that administration is continuedonly so long as is necessary to successfully treat the hyperlipidemiccondition.

A potential advantage of the combination therapy disclosed herein may bereduced dosage amount of of any individual therapeutic compound, or alltherapeutic compounds, effective in treating hyperlipidemic conditionssuch as atherosclerosis and hypercholesterolemia. The dosage loweringwill provide advantages including reduction of side effects of theindividual therapeutic compounds when compared to the monotherapy.

One of the several embodiments of the present invention comprises acombination therapy comprising the use of a first amount of an IBATinhibitor and a second amount of another cardiovascular therapeuticuseful in the prophylaxis or treatment of hyperlipidemia,atherosclerosis, or hypercholesterolemia wherein said first and secondamounts together comprise an anti-hyperlipidemic condition effectiveamount, an anti-atherosclerotic condition effective amount, or ananti-hypercholesterolemic condition effective amount of said compounds.For example one of the many embodiments of the present invention is acombination therapy comprising therapeutic dosages of an IBAT inhibitorand a CETP inhibitor. A preferred embodiment of the present invention isa combination therapy comprising therapeutic dosages of a benzothiepineIBAT inhibitor and a CETP inhibitor.

The embodiments of the present invention can comprise a combinationtherapy using two or more of the therapeutic compounds described orincorporated herein. The combination therapy can comprise two or moretherapeutic compounds from different classes of chemistry, e.g., an IBATinhibitor can be therapeutically combined with a CETP inhibitor.Therapeutic combinations can comprise more than two therapeuticcompounds. For example, the therapy can comprise the use of an IBATinhibitor, a CETP inhibitor, and a HMG CoA reductase inhibitor.Alternatively, two or more therapeutic compounds from the same class ofchemistry can comprise the therapy, e.g. a combination therapycomprising two or more IBAT inhibitors or two or more CETP inhibitors.

A further embodiment of the instant invention comprises the use of anyof the cardiovascular combination therapies described herein for theprophylaxis or treatment of hypercholesterolemia, atherosclerosis, orhyperlipidemia.

The following non-limiting examples serve to illustrate various aspectsof the present invention.

EXAMPLES

Table 3 illustrates examples of some of the many combinations of thepresent invention wherein the combination comprises a first amount ofIBAT inhibitor and a second amount of a CETP inhibitor, wherein saidfirst and second amounts together comprise an anti-hyperlipidemiccondition effective amount, an anti-atherosclerotic condition effectiveamount, or an anti-hypercholesterolemic condition effective amount ofsaid compounds.

TABLE 3 Example Component Component Number 1 2  1 B-1 C-1  2 B-1 C-2  3B-1 C-3  4 B-1 C-4  5 B-1 C-5  6 B-1 C-6  7 B-1 C-7  8 B-1 C-8  9 B-1C-9  10 B-1 C-10  11 B-1 C-11  12 B-1 C-12  13 B-1 C-13  14 B-1 C-14  15B-1 C-15  16 B-1 C-16  17 B-1 C-17  18 B-1 C-18  19 B-1 C-19  20 B-1C-20  21 B-2 C-1  22 B-2 C-2  23 B-2 C-3  24 B-2 C-4  25 B-2 C-5  26 B-2C-6  27 B-2 C-7  28 B-2 C-8  29 B-2 C-9  30 B-2 C-10  31 B-2 C-11  32B-2 C-12  33 B-2 C-13  34 B-2 C-14  35 B-2 C-15  36 B-2 C-16  37 B-2C-17  38 B-2 C-18  39 B-2 C-19  40 B-2 C-20  41 B-3 C-1  42 B-3 C-2  43B-3 C-3  44 B-3 C-4  45 B-3 C-5  46 B-3 C-6  47 B-3 C-7  48 B-3 C-8  49B-3 C-9  50 B-3 C-10  51 B-3 C-11  52 B-3 C-12  53 B-3 C-13  54 B-3 C-14 55 B-3 C-15  56 B-3 C-16  57 B-3 C-17  58 B-3 C-18  59 B-3 C-19  60 B-3C-20  61 B-4 C-1  62 B-4 C-2  63 B-4 C-3  64 B-4 C-4  65 B-4 C-5  66 B-4C-6  67 B-4 C-7  68 B-4 C-8  69 B-4 C-9  70 B-4 C-10  71 B-4 C-11  72B-4 C-12  73 B-4 C-13  74 B-4 C-14  75 B-4 C-15  76 B-4 C-16  77 B-4C-17  78 B-4 C-18  79 B-4 C-19  80 B-4 C-20  81 B-5 C-1  82 B-5 C-2  83B-5 C-3  84 B-5 C-4  85 B-5 C-5  86 B-5 C-6  87 B-5 C-7  88 B-5 C-8  89B-5 C-9  90 B-5 C-10  91 B-5 C-11  92 B-5 C-12  93 B-5 C-13  94 B-5 C-14 95 B-5 C-15  96 B-5 C-16  97 B-5 C-17  98 B-5 C-18  99 B-5 C-19 100 B-5C-20 101 B-6 C-1 102 B-6 C-2 103 B-6 C-3 104 B-6 C-4 105 B-6 C-5 106 B-6C-6 107 B-6 C-7 108 B-6 C-8 109 B-6 C-9 110 B-6 C-10 111 B-6 C-11 112B-6 C-12 113 B-6 C-13 114 B-6 C-14 115 B-6 C-15 116 B-6 C-16 117 B-6C-17 118 B-6 C-18 119 B-6 C-19 120 B-6 C-20 121 B-7 C-1 122 B-7 C-2 123B-7 C-3 124 B-7 C-4 125 B-7 C-5 126 B-7 C-6 127 B-7 C-7 128 B-7 C-8 129B-7 C-9 130 B-7 C-10 131 B-7 C-11 132 B-7 C-12 133 B-7 C-13 134 B-7 C-14135 B-7 C-15 136 B-7 C-16 137 B-7 C-17 138 B-7 C-18 139 B-7 C-19 140 B-7C-20 141 B-8 C-1 142 B-8 C-2 143 B-8 C-3 144 B-8 C-4 145 B-8 C-5 146 B-8C-6 147 B-8 C-7 148 B-8 C-8 149 B-8 C-9 150 B-8 C-10 151 B-8 C-11 152B-8 C-12 153 B-8 C-13 154 B-8 C-14 155 B-8 C-15 156 B-8 C-16 157 B-8C-17 158 B-8 C-18 159 B-8 C-19 160 B-8 C-20 161 B-9 C-1 162 B-9 C-2 163B-9 C-3 164 B-9 C-4 165 B-9 C-5 166 B-9 C-6 167 B-9 C-7 168 B-9 C-8 169B-9 C-9 170 B-9 C-10 171 B-9 C-11 172 B-9 C-12 173 B-9 C-13 174 B-9 C-14175 B-9 C-15 176 B-9 C-16 177 B-9 C-17 178 B-9 C-18 179 B-9 C-19 180 B-9C-20 181 B-10 C-1 182 B-10 C-2 183 B-10 C-3 184 B-10 C-4 185 B-10 C-5186 B-10 C-6 187 B-10 C-7 188 B-10 C-8 189 B-10 C-9 190 B-10 C-10 191B-10 C-11 192 B-10 C-12 193 B-10 C-13 194 B-10 C-14 195 B-10 C-15 196B-10 C-16 197 B-10 C-17 198 B-10 C-18 199 B-10 C-19 200 B-10 C-20 201B-11 C-1 202 B-11 C-2 203 B-11 C-3 204 B-11 C-4 205 B-11 C-5 206 B-11C-6 207 B-11 C-7 208 B-11 C-8 209 B-11 C-9 210 B-11 C-10 211 B-11 C-11212 B-11 C-12 213 B-11 C-13 214 B-11 C-14 215 B-11 C-15 216 B-11 C-16217 B-11 C-17 218 B-11 C-18 219 B-11 C-19 220 B-11 C-20 221 B-12 C-1 222B-12 C-2 223 B-12 C-3 224 B-12 C-4 225 B-12 C-5 226 B-12 C-6 227 B-12C-7 228 B-12 C-8 229 B-12 C-9 230 B-12 C-10 231 B-12 C-11 232 B-12 C-12233 B-12 C-13 234 B-12 C-14 235 B-12 C-15 236 B-12 C-16 237 B-12 C-17238 B-12 C-18 239 B-12 C-19 240 B-12 C-20 241 B-13 C-1 242 B-13 C-2 243B-13 C-3 244 B-13 C-4 245 B-13 C-5 246 B-13 C-6 247 B-13 C-7 248 B-13C-8 249 B-13 C-9 250 B-13 C-10 251 B-13 C-11 252 B-13 C-12 253 B-13 C-13254 B-13 C-14 255 B-13 C-15 256 B-13 C-16 257 B-13 C-17 258 B-13 C-18259 B-13 C-19 260 B-13 C-20 261 B-14 C-1 262 B-14 C-2 263 B-14 C-3 264B-14 C-4 265 B-14 C-5 266 B-14 C-6 267 B-14 C-7 268 B-14 C-8 269 B-14C-9 270 B-14 C-10 271 B-14 C-11 272 B-14 C-12 273 B-14 C-13 274 B-14C-14 275 B-14 C-15 276 B-14 C-16 277 B-14 C-17 278 B-14 C-18 279 B-14C-19 280 B-14 C-20 281 B-15 C-1 282 B-15 C-2 283 B-15 C-3 284 B-15 C-4285 B-15 C-5 286 B-15 C-6 287 B-15 C-7 288 B-15 C-8 289 B-15 C-9 290B-15 C-10 291 B-15 C-11 292 B-15 C-12 293 B-15 C-13 294 B-15 C-14 295B-15 C-15 296 B-15 C-16 297 B-15 C-17 298 B-15 C-18 299 B-15 C-19 300B-15 C-20 301 B-16 C-1 302 B-16 C-2 303 B-16 C-3 304 B-16 C-4 305 B-16C-5 306 B-16 C-6 307 B-16 C-7 308 B-16 C-8 309 B-16 C-9 310 B-16 C-10311 B-16 C-11 312 B-16 C-12 313 B-16 C-13 314 B-16 C-14 315 B-16 C-15316 B-16 C-16 317 B-16 C-17 318 B-16 C-18 319 B-16 C-19 320 B-16 C-20321 B-17 C-1 322 B-17 C-2 323 B-17 C-3 324 B-17 C-4 325 B-17 C-5 326B-17 C-6 327 B-17 C-7 328 B-17 C-8 329 B-17 C-9 330 B-17 C-10 331 B-17C-11 332 B-17 C-12 333 B-17 C-13 334 B-17 C-14 335 B-17 C-15 336 B-17C-16 337 B-17 C-17 338 B-17 C-18 339 B-17 C-19 340 B-17 C-20 341 B-18C-1 342 B-18 C-2 343 B-18 C-3 344 B-18 C-4 345 B-18 C-5 346 B-18 C-6 347B-18 C-7 348 B-18 C-8 349 B-18 C-9 350 B-18 C-10 351 B-18 C-11 352 B-18C-12 353 B-18 C-13 354 B-18 C-14 355 B-18 C-15 356 B-18 C-16 357 B-18C-17 358 B-18 C-18 359 B-18 C-19 360 B-18 C-20 361 B-19 C-1 362 B-19 C-2363 B-19 C-3 364 B-19 C-4 365 B-19 C-5 366 B-19 C-6 367 B-19 C-7 368B-19 C-8 369 B-19 C-9 370 B-19 C-10 371 B-19 C-11 372 B-19 C-12 373 B-19C-13 374 B-19 C-14 375 B-19 C-15 376 B-19 C-16 377 B-19 C-17 378 B-19C-18 379 B-19 C-19 380 B-19 C-20 381 B-20 C-1 382 B-20 C-2 383 B-20 C-3384 B-20 C-4 385 B-20 C-5 386 B-20 C-6 387 B-20 C-7 388 B-20 C-8 389B-20 C-9 390 B-20 C-10 391 B-20 C-11 392 B-20 C-12 393 B-20 C-13 394B-20 C-14 395 B-20 C-15 396 B-20 C-16 397 B-20 C-17 398 B-20 C-18 399B-20 C-19 400 B-20 C-20 401 B-21 C-1 402 B-21 C-2 403 B-21 C-3 404 B-21C-4 405 B-21 C-5 406 B-21 C-6 407 B-21 C-7 408 B-21 C-8 409 B-21 C-9 410B-21 C-10 411 B-21 C-11 412 B-21 C-12 413 B-21 C-13 414 B-21 C-14 415B-21 C-15 416 B-21 C-16 417 B-21 C-17 418 B-21 C-18 419 B-21 C-19 420B-21 C-20 421 B-22 C-1 422 B-22 C-2 423 B-22 C-3 424 B-22 C-4 425 B-22C-5 426 B-22 C-6 427 B-22 C-7 428 B-22 C-8 429 B-22 C-9 430 B-22 C-10431 B-22 C-11 432 B-22 C-12 433 B-22 C-13 434 B-22 C-14 435 B-22 C-15436 B-22 C-16 437 B-22 C-17 438 B-22 C-18 439 B-22 C-19 440 B-22 C-20441 B-23 C-1 442 B-23 C-2 443 B-23 C-3 444 B-23 C-4 445 B-23 C-5 446B-23 C-6 447 B-23 C-7 448 B-23 C-8 449 B-23 C-9 450 B-23 C-10 451 B-23C-11 452 B-23 C-12 453 B-23 C-13 454 B-23 C-14 455 B-23 C-15 456 B-23C-16 457 B-23 C-17 458 B-23 C-18 459 B-23 C-19 460 B-23 C-20 461 B-24C-1 462 B-24 C-2 463 B-24 C-3 464 B-24 C-4 465 B-24 C-5 466 B-24 C-6 467B-24 C-7 468 B-24 C-8 469 B-24 C-9 470 B-24 C-10 471 B-24 C-11 472 B-24C-12 473 B-24 C-13 474 B-24 C-14 475 B-24 C-15 476 B-24 C-16 477 B-24C-17 478 B-24 C-18 479 B-24 C-19 480 B-24 C-20 481 B-25 C-1 482 B-25 C-2483 B-25 C-3 484 B-25 C-4 485 B-25 C-5 486 B-25 C-6 487 B-25 C-7 488B-25 C-8 489 B-25 C-9 490 B-25 C-10 491 B-25 C-11 492 B-25 C-12 493 B-25C-13 494 B-25 C-14 495 B-25 C-15 496 B-25 C-16 497 B-25 C-17 498 B-25C-18 499 B-25 C-19 500 B-25 C-20 501 B-26 C-1 502 B-26 C-2 503 B-26 C-3504 B-26 C-4 505 B-26 C-5 506 B-26 C-6 507 B-26 C-7 508 B-26 C-8 509B-26 C-9 510 B-26 C-10 511 B-26 C-11 512 B-26 C-12 513 B-26 C-13 514B-26 C-14 515 B-26 C-15 516 B-26 C-16 517 B-26 C-17 518 B-26 C-18 519B-26 C-19 520 B-26 C-20 521 B-27 C-1 522 B-27 C-2 523 B-27 C-3 524 B-27C-4 525 B-27 C-5 526 B-27 C-6 527 B-27 C-7 528 B-27 C-8 529 B-27 C-9 530B-27 C-10 531 B-27 C-11 532 B-27 C-12 533 B-27 C-13 534 B-27 C-14 535B-27 C-15 536 B-27 C-16 537 B-27 C-17 538 B-27 C-18 539 B-27 C-19 540B-27 C-20 541 B-28 C-1 542 B-28 C-2 543 B-28 C-3 544 B-28 C-4 545 B-28C-5 546 B-28 C-6 547 B-28 C-7 548 B-28 C-8 549 B-28 C-9 550 B-28 C-10551 B-28 C-11 552 B-28 C-12 553 B-28 C-13 554 B-28 C-14 555 B-28 C-15556 B-28 C-16 557 B-28 C-17 558 B-28 C-18 559 B-28 C-19 560 B-28 C-20561 B-29 C-1 562 B-29 C-2 563 B-29 C-3 564 B-29 C-4 565 B-29 C-5 566B-29 C-6 567 B-29 C-7 568 B-29 C-8 569 B-29 C-9 570 B-29 C-10 571 B-29C-11 572 B-29 C-12 573 B-29 C-13 574 B-29 C-14 575 B-29 C-15 576 B-29C-16 577 B-29 C-17 578 B-29 C-18 579 B-29 C-19 580 B-29 C-20 581 B-30C-1 582 B-30 C-2 583 B-30 C-3 584 B-30 C-4 585 B-30 C-5 586 B-30 C-6 587B-30 C-7 588 B-30 C-8 589 B-30 C-9 590 B-30 C-10 591 B-30 C-11 592 B-30C-12 593 B-30 C-13 594 B-30 C-14 595 B-30 C-15 596 B-30 C-16 597 B-30C-17 598 B-30 C-18 599 B-30 C-19 600 B-30 C-20 601 B-31 C-1 602 B-31 C-2603 B-31 C-3 604 B-31 C-4 605 B-31 C-5 606 B-31 C-6 607 B-31 C-7 608B-31 C-8 609 B-31 C-9 610 B-31 C-10 611 B-31 C-11 612 B-31 C-12 613 B-31C-13 614 B-31 C-14 615 B-31 C-15 616 B-31 C-16 617 B-31 C-17 618 B-31C-18 619 B-31 C-19 620 B-31 C-20 621 B-32 C-1 622 B-32 C-2 623 B-32 C-3624 B-32 C-4 625 B-32 C-5 626 B-32 C-6 627 B-32 C-7 628 B-32 C-8 629B-32 C-9 630 B-32 C-10 631 B-32 C-11 632 B-32 C-12 633 B-32 C-13 634B-32 C-14 635 B-32 C-15 636 B-32 C-16 637 B-32 C-17 638 B-32 C-18 639B-32 C-19 640 B-32 C-20 641 B-33 C-1 642 B-33 C-2 643 B-33 C-3 644 B-33C-4 645 B-33 C-5 646 B-33 C-6 647 B-33 C-7 648 B-33 C-8 649 B-33 C-9 650B-33 C-10 651 B-33 C-11 652 B-33 C-12 653 B-33 C-13 654 B-33 C-14 655B-33 C-15 656 B-33 C-16 657 B-33 C-17 658 B-33 C-18 659 B-33 C-19 660B-33 C-20 661 B-34 C-1 662 B-34 C-2 663 B-34 C-3 664 B-34 C-4 665 B-34C-5 666 B-34 C-6 667 B-34 C-7 668 B-34 C-8 669 B-34 C-9 670 B-34 C-10671 B-34 C-11 672 B-34 C-12 673 B-34 C-13 674 B-34 C-14 675 B-34 C-15676 B-34 C-16 677 B-34 C-17 678 B-34 C-18 679 B-34 C-19 680 B-34 C-20681 B-35 C-1 682 B-35 C-2 683 B-35 C-3 684 B-35 C-4 685 B-35 C-5 686B-35 C-6 687 B-35 C-7 688 B-35 C-8 689 B-35 C-9 690 B-35 C-10 691 B-35C-11 692 B-35 C-12 693 B-35 C-13 694 B-35 C-14 695 B-35 C-15 696 B-35C-16 697 B-35 C-17 698 B-35 C-18 699 B-35 C-19 700 B-35 C-20 701 B-36C-1 702 B-36 C-2 703 B-36 C-3 704 B-36 C-4 705 B-36 C-5 706 B-36 C-6 707B-36 C-7 708 B-36 C-8 709 B-36 C-9 710 B-36 C-10 711 B-36 C-11 712 B-36C-12 713 B-36 C-13 714 B-36 C-14 715 B-36 C-15 716 B-36 C-16 717 B-36C-17 718 B-36 C-18 719 B-36 C-19 720 B-36 C-20 721 B-37 C-1 722 B-37 C-2723 B-37 C-3 724 B-37 C-4 725 B-37 C-5 726 B-37 C-6 727 B-37 C-7 728B-37 C-8 729 B-37 C-9 730 B-37 C-10 731 B-37 C-11 732 B-37 C-12 733 B-37C-13 734 B-37 C-14 735 B-37 C-15 736 B-37 C-16 737 B-37 C-17 738 B-37C-18 739 B-37 C-19 740 B-37 C-20 741 B-38 C-1 742 B-38 C-2 743 B-38 C-3744 B-38 C-4 745 B-38 C-5 746 B-38 C-6 747 B-38 C-7 748 B-38 C-8 749B-38 C-9 750 B-38 C-10 751 B-38 C-11 752 B-38 C-12 753 B-38 C-13 754B-38 C-14 755 B-38 C-15 756 B-38 C-16 757 B-38 C-17 758 B-38 C-18 759B-38 C-19 760 B-38 C-20 761 B-40 C-1 762 B-40 C-2 763 B-40 C-3 764 B-40C-4 765 B-40 C-5 766 B-40 C-6 767 B-40 C-7 768 B-40 C-8 769 B-40 C-9 770B-40 C-10 771 B-40 C-11 772 B-40 C-12 773 B-40 C-13 774 B-40 C-14 775B-40 C-15 776 B-40 C-16 777 B-40 C-17 778 B-40 C-18 779 B-40 C-19 780B-40 C-20

Biological Assays

The utility of the combinations of the present invention can be shown bythe following assays. These assays are performed in vitro and in animalmodels essentially using procedures recognized to show the utility ofthe present invention.

In Vitro Assay of Compounds that Inhibit IBAT-mediated Uptake of[¹⁴C]-Taurocholate (TC) in H14 Cells

Baby hamster kidney cells (BHK) transfected with the cDNA of human IBAT(H14 cells) are seeded at 60,000 cells/well in 96 well Top-Count tissueculture plates for assays run within in 24 hours of seeding, 30,000cells/well for assays run within 48 hours, and 10,000 cells/well forassays run within 72 hours.

On the day of assay, the cell monolayer is gently washed once with 100μl assay buffer (Dulbecco's Modified Eagle's medium with 4.5 g/Lglucose+0.2% (w/v) fatty acid free bovine serum albumin-(FAF)BSA). Toeach well 50 μl of a two-fold concentrate of test compound in assaybuffer is added along with 50 μl of 6 μM [¹⁴C]-taurocholate in assaybuffer (final concentration of 3 μM [¹⁴C]-taurocholate). The cellculture plates are incubated 2 hours at 37° C. prior to gently washingeach well twice with 100 μl 4° C. Dulbecco's phosphate-buffered saline(PBS) containing 0.2% (w/v) (FAF)BSA. The wells are then gently washedonce with 100 μl 4° C. PBS without (FAF)BSA. To each 200 μl of liquidscintillation counting fluid is added, the plates are heat sealed andshaken for 30 minutes at room temperature prior to measuring the amountof radioactivity in each well on a Packard Top-Count instrument.

In Vitro Assay of Compounds that Inhibit Uptake of [¹⁴C]-Alanine

The alanine uptake assay is performed in an identical fashion to thetaurocholate assay, with the exception that labeled alanine issubstituted for the labeled taurocholate.

Measurement of Rat Fecal Bile Acid Concentration (FBA)

Total fecal output from individually housed rats is collected for 24 or48 hours, dried under a stream of nitrogen, pulverized, mixed, andweighed. Approximately 0.1 gram is weighed out and extracted into anorganic solvent (butanol/water). Following separation and drying, theresidue is dissolved in methanol and the amount of bile acid present ismeasured enzymatically using the 3α-hydroxysteroid steroid dehydrogenasereaction with bile acids to reduce NAD. (see Mashige, F. et al. Clin.Chem., 27, 1352 (1981), herein incorporated by reference).

Rat Gavage Assay

Male Wister rats (275-300 g) are to be administered IBAT inhibitorsusing an oral gavage procedure. Drug or vehicle 0.2% TWEEN 80 in water)is administered once a day (9:00-10:00 a.m.) for 4 days at varyingdosages in a final volume of 2 mL per kilogram of body weight. (TWEEN 80is a 20 molar polyethyleneoxide sorbitan monooleate surfactantmanufactured by ICI Specialty Chemicals, Wilmington, Del. U.S.A.) Totalfecal samples are collected during the final 48 hours of the treatmentperiod and analyzed for bile acid content using an enzymatic assay asdescribed below. Compound efficacy will be determined by comparison ofthe increase in fecal bile acid (FBA) concentration in treated rats tothe mean FBA concentration of rats in the vehicle group.

[³H]Taurocholate Uptake in Rabbit Brush Border Membrane Vesicles (BBMV)

Rabbit Ileal brush border membranes are to be prepared from frozen ilealmucosa by the calcium precipitation method describe by Malathi et al.(Biochimica Biophysica Acta, 554, 259 (1979), herein incorporated byreference). The method for measuring taurocholate is essentially asdescribed by Kramer et al. (Biochimica Biophysica Acta, 1111, 93 (1992),herein incorporated by reference) except the assay volume will be 200 μlinstead of 100 μl. Briefly, at room temperature a 190 μl solutioncontaining 2 μM [³H]-taurocholate(0.75 μCi), 20 mM tris, 100 mM NaCl,100 mM mannitol pH 7.4 is incubated for 5 sec with 10 μl of brush bordermembrane vesicles (60-120 μg protein). The incubation is initiated bythe addition of the BBMV while vortexing and the reaction is to bestopped by the addition of 5 ml of ice cold buffer (20 mM Hepes-tris,150 mM KCl) followed immediately by filtration through a nylon filter(0.2 μm pore) and an additional 5 ml wash with stop buffer.

Measurement of Hepatic Cholesterol Concentration (HEPATIC CHOL)

Liver tissue is to be weighed and homogenized in chloroform:methanol(2:1). After homogenization and centrifugation the supernatant isseparated and dried under nitrogen. The residue is to be dissolved inisopropanol and the cholesterol content will be measured enzymatically,using a combination of cholesterol oxidase and peroxidase, as describedby Allain, C. A. et al., Clin. Chem., 20, 470 (1974) (hereinincorporated by reference).

Measurement of Hepatic HMG CoA-Reductase Activity (HMG COA)

Hepatic microsomes are to be prepared by homogenizing liver samples in aphosphate/sucrose buffer, followed by centrifugal separation. The finalpelleted material is resuspended in buffer and an aliquot will beassayed for HMG CoA reductase activity by incubating for 60 minutes at37° C. in the presence of ¹⁴C-HMG-CoA (Dupont-NEN). The reaction isstopped by adding 6N HCl followed by centrifugation. An aliquot of thesupernatant is separated, by thin-layer chromatography, and the spotcorresponding to the enzyme product is scraped off the plate, extractedand radioactivity is determined by scintillation counting. (Reference:Akerlund, J. and Bjorkhem, I. (1990) J. Lipid Res. 31, 2159).

Measurement of Hepatic Cholesterol 7-α-Hydroxylase Activity (7a-OHase)

Hepatic microsomes are to be prepared by homogenizing liver samples in aphosphate/sucrose buffer, followed by centrifugal separation. The finalpelleted material is resuspended in buffer and an aliquot will beassayed for cholesterol 7-α-hydroxylase activity by incubating for 5minutes at 37° C. in the presence of NADPH. Following extraction intopetroleum ether, the organic solvent is evaporated and the residue isdissolved in acetonitrile/methanol. The enzymatic product will beseparated by injecting an aliquot of the extract onto a C₁₈ reversedphase HPLC column and quantitating the eluted material using UVdetection at 240 nm. (Reference: Horton, J. D., et al. (1994) J. Clin.Invest. 93, 2084).

Determination of Serum Cholesterol (SER.CHOL, HDL-CHOL, TGI andVLDL+LDL)

Total serum cholesterol (SER.CHOL) are to be measured enzymaticallyusing a commercial kit from Wako Fine Chemicals (Richmond, Va.);Cholesterol C11, Catalog No. 276-64939. HDL cholesterol (HDL-CHOL) willbe assayed using this same kit after precipitation of VLDL and LDL withSigma Chemical Co. HDL Cholesterol reagent, Catalog No. 352-3 (dextransulfate method). Total serum triglycerides (blanked) (TGI) will beassayed enzymatically with Sigma Chemical Co. GPO-Trinder, Catalog No.337-B. VLDL and LDL (VLDL+LDL) cholesterol concentrations will becalculated as the difference between total and HDL cholesterol.

Measurement of Hamster Fecal Bile Acid Concentration (FBA)

Total fecal output from individually housed hamsters is to be collectedfor 24 or 48 hours, dried under a stream of nitrogen, pulverized andweighed. Approximately 0.1 gram is weighed out and extracted into anorganic solvent (butanol/water). Following separation and drying, theresidue is dissolved in methanol and the amount of bile acid present ismeasured enzymatically using the 3α-hydroxysteroid steroid dehydrogenasereaction with bile acids to reduce NAD. (Mashige, F. et al. Clin. Chem.,27, 1352 (1981), herein incorporated by reference).

Dog Model for Evaluating Lipid Lowering Drugs

Male beagle dogs, obtained from a vendor such as Marshall farms andweighing 6-12 kg are fed once a day for two hours and given water adlibitum. Dogs may be randomly assigned to a dosing groups consisting of6 to 12 dogs each, such as: vehicle, i.g.; 1 mg/kg, i.g.; 2 mg/kg, i.g.;4 mg/kg, i.g.; 2 mg/kg, p.o. (powder in capsule). Intra-gastric dosingof a therapeutic material dissolved in aqueous solution (for example,0.2% Tween 80 solution [polyoxyethylene mono-oleate, Sigma Chemical Co.,St. Louis, Mo.]) may be done using a gavage tube. Prior to initiatingdosing, blood samples may be drawn from the cephalic vein in the morningbefore feeding in order to evaluate serum cholesterol (total and HDL)and triglycerides. For several consecutive days animals are dosed in themorning, prior to feeding. Animals are to be allowed 2 hours to eatbefore any remaining food is removed. Feces are to be collected over a 2day period at the end of the study and may be analyzed for bile acid orlipid content. Blood samples are also to be taken, at the end of thetreatment period, for comparison with pre-study serum lipid levels.Statistical significance will be determined using the standard student'sT-test with p<.05.

Dog Serum Lipid Measurement

Blood is to be collected from the cephalic vein of fasted dogs in serumseparator tubes (Vacutainer SST, Becton Dickinson and Co., FranklinLakes, N.J.). The blood is centrifuged at 2000 rpm for 20 minutes andthe serum decanted.

Total cholesterol may be measured in a 96 well format using a Wakoenzymatic diagnostic kit (Cholesterol CII) (Wako Chemicals, Richmond,Va.), utilizing the cholesterol oxidase reaction to produce hydrogenperoxide which is measured colorimetrically. A standard curve from 0.5to 10 μg cholesterol is to be prepared in the first 2 columns of theplate. The serum samples (20-40 μl, depending on the expected lipidconcentration) or known serum control samples are added to separatewells in duplicate. Water is added to bring the volume to 100 μl in eachwell. A 100 μl aliquot of color reagent is added to each well and theplates will be read at 500 nm after a 15 minute incubation at 37 degreescentigrade.

HDL cholesterol may be assayed using Sigma kit No. 352-3 (Sigma ChemicalCo., St. Louis, Mo.) which utilizes dextran sulfate and Mg ions toselectively precipitate LDL and VLDL. A volume of 150 μl of each serumsample is to be added to individual microfuge tubes, followed by 15 μlof HDL cholesterol reagent (Sigma 352-3). Samples are to be mixed andcentrifuged at 5000 rpm for 5 minutes. A 50 μl aliquot of thesupernatant is to be then mixed with 200 μl of saline and assayed usingthe same procedure as for total cholesterol measurement.

Triglycerides are to be measured using Sigma kit No. 337 in a 96 wellplate format. This procedure will measure glycerol, following itsrelease by reaction of triglycerides with lipoprotein lipase. Standardsolutions of glycerol (Sigma 339-11) ranging from 1 to 24 μg are to beused to generate the standard curve. Serum samples (20-40 μl, dependingon the expected lipid concentration) are added to wells in duplicate.Water is added to bring the volume to 100 μl in each well and 100 μl ofcolor reagent is also added to each well. After mixing and a 15 minuteincubation, the plates will be read at 540 nm and the triglyceridevalues calculated from the standard curve. A replicate plate is also tobe run using a blank enzyme reagent to correct for any endogenousglycerol in the serum samples.

Dog Fecal Bile Acid Measurement

Fecal samples may be collected to determine the fecal bile acid (FBA)concentration for each animal. Fecal collections may be made during thefinal 48 hours of the study, for two consecutive 24 hour periods between9:00 am and 10:00 am each day, prior to dosing and feeding. The separatetwo day collections from each animal are to be weighed, combined andhomogenized with distilled water in a processor (Cuisinart) to generatea homogeneous slurry. About 1.4 g of the homogenate is to be extractedin a final concentration of 50% tertiary butanol/distilled water (2:0.6)for 45 minutes in a 37° C. water bath and centrifuged for 13 minutes at2000×g. The concentration of bile acids (mmoles/day) may be determinedusing a 96-well enzymatic assay system (1,2). A 20 μl aliquot of thefecal extract is to be added to two sets each of triplicate wells in a96-well assay plate. A standardized sodium taurocholate solution and astandardized fecal extract solution (previously made from pooled samplesand characterized for its bile acid concentration) will also analyzedfor assay quality control. Twenty-microliter aliquots of sodiumtaurocholate, serially diluted to generate a standard curve aresimilarly to be added to two sets of triplicate wells. A 230 μl reactionmixture containing 1M hydrazine hydrate, 0.1 M pyrophosphate and 0.46mg/ml NAD is to be added to each well. A 50 μl aliquot of3a-hydroxysteroid-dehydrogenase enzyme (HSD; 0.8 units/ml) or assaybuffer (0.1 M sodium pyrophosphate) are then added to one of the twosets of triplicates. All reagents may be obtained from Sigma ChemicalCo., St. Louis, Mo. Following 60 minutes of incubation at roomtemperature, the optical density at 340 nm will be measured and the meanof each set of triplicate samples will be calculated. The difference inoptical density±HSD enzyme is to be used to determine the bile acidconcentration (mM) of each sample based on the sodium taurocholatestandard curve. The bile acid concentration of the extract, the weightof the fecal homogenate (grams) and the body weight of the animal are tobe used to calculate the corresponding FBA concentration inmmoles/kg/day for each animal. The mean FBA concentration(mmoles/kg/day) of the vehicle group is to be subtracted from the FBAconcentration of each treatment group to determine the increase (deltavalue) in FBA concentration as a result of the treatment.

Plasma Lipids Assay in Rabbits

Plasma lipids can be assayed using standard methods as reported by J.R.Schuh et al., J. Clin. Invest., 91, 1453-1458 (1993), hereinincorporated by reference. Groups of male, New Zealand white rabbits areplaced on a standard diet (100 g/day) supplemented with 0.3% cholesteroland 2% corn oil (Zeigler Bothers, Inc., Gardners, Pa.). Water isavailable ad lib. Groups of control and treated animals are killed after1 and 3 months of treatment. Tissues are removed for characterization ofatherosclerotic lesions. Blood samples are taken for determination ofplasma lipid concentrations.

Plasma Lipids

Plasma for lipid analysis is obtained by withdrawing blood from the earvein into EDTA-containing tubes (Vacutainer; Becton Dickenson & Co.,Rutherford, N.J.), followed by centrifugal separation of the cells.Total cholesterol is determined enzymatically, using the cholesteroloxidase reaction (C. A. Allain et al., Clin. Chem., 20, 470-475 (1974),herein incorporated by reference). HDL cholesterol is also measuredenzymatically, after selective precipitation of LDL and VLDL by dextransulfate with magnesium (G. R. Warnick et al., Clin. Chem., 28, 1379-1388(1982), herein incorporated by reference). Plasma triglyceride levelsare determined by measuring the amount of glycerol released bylipoprotein lipase through an enzyme-linked assay (G. Bucolo et al.,Clin. Chem., 19, 476-482 (1973), herein incorporated by reference).

Atherosclerosis

Animals are killed by pentobarbital injection. Thoracic aortas arerapidly removed, immersion fixed in 10% neutral buffered formalin, andstained with oil red 0 (0.3%). After a single longitudinal incisionalong the wall opposite the arterial ostia, the vessels are pinned openfor evaluation of the plaque area. The percent plaque coverage isdetermined from the values for the total area examined and the stainedarea, by threshold analysis using a true color image analyzer(Videometric 150; American Innovision, Inc., San Diego, Calif.)interfaced to a color camera (Toshiba 3CCD) mounted on a dissectingmicroscope. Tissue cholesterol will be measured enzymatically asdescribed, after extraction with a chloroform/methanol mixture (2:1)according to the method of Folch et al. (J. Biol. Chem., 226, 497-509(1957), herein incorporated by reference).

In Vitro Vascular Response

The abdominal aortas are rapidly excised, after injection of sodiumpentobarbital, and placed in oxygenated Krebs-bicarbonate buffer. Afterremoval of perivascular tissue, 3-mm ring segments are cut, placed in a37° C. muscle bath containing Krebs-bicarbonate solution, and suspendedbetween two stainless steel wires, one of which is attached to a forcetransducer (Grass Instrument Co., Quincy, Mass.). Force changes inresponse to angiotensin II added to the bath will be recorded on a chartrecorder.

CETP Activity Assay in Human Plasma (Tritiated Cholesteryl Ester)

Blood is to be obtained from healthy volunteers. Blood is collected intubes containing EDTA (EDTA plasma pool). The EDTA human plasma poolpreviously stored at −20° C., is to be thawed at room temperature, andcentrifuged for 5 minutes to remove any particulate matter. TritiatedHDL, radiolabeled in the cholesteryl ester moiety ([³H]CE-HDL) asdescribed by Morton and Zilversmit (J. Biol. Chem., 256, 11992-95(1981)), is to be added to the plasma to a final concentration of (25μg/ml cholesterol). Inhibitor compounds are to be added to the plasma asfollows: Equal volumes of the plasma containing the [³H]CE-HDL (396 μl)are added by pipette into micro tubes (Titertube, Bio-Rad laboratories,Hercules, Calif.). Compounds, usually dissolved as 20-50 mM stocksolutions in DMSO, are to be serially diluted in DMSO (or an alternativesolvent in some cases, such as dimethylformamide or ethanol). Four μl ofeach of the serial dilutions of inhibitor compounds or DMSO alone arethen added to each of the plasma tubes. The tubes are immediately mixed.Triplicate aliquots (100 μl ) from each plasma tube are then transferredto wells of 96-well round-bottomed polystyrene microtiter plates(Corning, Corning, N.Y.). Plates are sealed with plastic film andincubated at 37° C. for 4 hours. Test wells are to contain plasma withdilutions of inhibitor compounds. Control wells are to contain plasmawith DMSO alone. Blank wells are to contain plasma with DMSO alone thatare left in the micro tubes at 4° C. for the 4 hour incubation and areadded to the microtiter wells at the end of the incubation period. VLDLand LDL are precipitated by the addition of 10 μl of precipitatingreagent (1% (w/v) dextran sulfate (Dextralip50)/0.5 M magnesiumchloride, pH 7.4) to all wells. The wells are mixed on a plate mixer andthen incubated at ambient temperature for 10 min. The plates are thencentrifuged at 1000×g for 30 min at 10° C. The supernatants (50 μl) fromeach well are then transferred to Picoplate™ 96 plate wells (Packard,Meriden, Conn.) containing 250:1 Microscint™-40 (Packard, Meriden,Conn.). The places are heat-sealed (TopSeal™-P, Packard, Meriden, Conn.)according to the manufacturer's directions and mixed for 30 min.Radioactivity will be measured on a microplate scintillation counter(TopCount, Packard, Meriden, Conn.). IC₅₀ values will be determined asthe concentration of inhibitor compound inhibiting transfer of [³H]CEfrom the supernatant [³H]CE-HDL to the precipitated VLDL and LDL by 50%compared to the transfer obtained in the control wells. The maximumpercentage transfer (in the control wells) will be determined using thefollowing equation:${\% \quad {Transfer}} = \frac{\left\lbrack {{dpm}_{blank} - {dpm}_{control}} \right\rbrack \times 100}{{dpm}_{blank}}$

The percentage of control transfer determined in the wells containinginhibitor compounds is determined as follows:${\% \quad {Control}} = \frac{\left\lbrack {{dpm}_{blank} - {dpm}_{test}} \right\rbrack \times 100}{{dpm}_{blank} - {dpm}_{control}}$

IC₅₀ values will be calculated from plots of % control versusconcentration of inhibitor compound.

CETP Activity In Vitro

The ability of compounds to inhibit CETP activity are assessed using anin vitro assay that measures the rate of transfer of radiolabeledcholesteryl ester ([³H]CE) from HDL donor particles to LDL acceptorparticles. Details of the assay are provided by Glenn et al. (Glenn andMelton, “Quantification of Cholesteryl Ester Transfer Protein (CETP): A)CETP Activity and B) Immunochemical Assay of CETP Protein,” Meth.Enzymol., 263, 339-351 (1996)). CETP can be obtained from the serum-freeconditioned medium of CHO cells transfected with a cDNA for CETP (Wang,S. et al. J. Biol. Chem. 267, 17487-17490 (1992)). To measure CETPactivity, [³H]CE-labeled HDL, LDL, CETP and assay buffer (50 mMtris(hydroxymethyl)aminomethane, pH 7.4; 150 mM sodium chloride; 2 mMethylenediamine-tetraacetic acid; 1% bovine serum albumin) are incubatedin a volume of 200 μl, for 2 hours at 37° C. in 96 well plates. LDL isdifferentially precipitated by the addition of 50 μl of 1% (w/v) dextransulfate/0.5 M magnesium chloride, mixed by vortex, and incubated at roomtemperature for 10 minutes. The solution (200 μl) is transferred to afilter plate (Millipore). After filtration, the radioactivity present inthe precipitated LDL is measured by liquid scintillation counting.Correction for non-specific transfer or precipitation is made byincluding samples that do not contain CETP. The rate of [³H]CE transferusing this assay is linear with respect to time and CETP concentration,up to 25-30% of [³H]CE transferred.

The potency of test compounds can be determined by performing the abovedescribed assay in the presence of varying concentrations of the testcompounds and determining the concentration required for 50% inhibitionof transfer of [³H]CE from HDL to LDL. This value is defined as theIC₅₀. The IC₅₀ values determined from this assay are accurate when theIC₅₀ is greater than 10 nM. In the case where compounds have greaterinhibitory potency, accurate measurements of IC₅₀ may be determinedusing longer incubation times (up to 18 hours) and lower final.concentrations of CETP (<50 nM).

Inhibition of CETP Activity In Vivo

Inhibition of CETP activity by a test compound can be determined byadministering the compound to an animal by intravenous injection or oralgavage, measuring the amount of transfer of tritium-labeled cholesterylester ([³H]CE) from HDL to VLDL and LDL particles, and comparing thisamount of transfer with the amount of transfer observed in controlanimals.

Male golden Syrian hamsters are maintained on a diet of chow containing0.24% cholesterol for at least two weeks prior to the study. For animalsreceiving intravenous dosing, immediately before the experiment, animalsare anesthetized with pentobarbital. Anesthesia is maintained throughoutthe experiment. In-dwelling catheters are inserted into the jugular veinand carotid artery. At the start of the experiment all animals willreceive 0.2 ml of a solution containing [³H]CE-HDL into the jugularvein. [³H]CE-HDL is a preparation of human HDL containingtritium-labeled cholesteryl ester, and is prepared according to themethod of Glenn et al. (Meth. Enzymol., 263, 339-351 (1996)). Testcompound is dissolved as a 80 mM stock solution in vehicle (2% ethanol:98% PEG 400, Sigma Chemical Company, St. Louis, Mo. USA) andadministered either by bolus injection or by continuous infusion. Twominutes after the [³H]CE-HDL dose is administered, animals receive 0.1ml of the test solution injected into the jugular vein. Control animalsreceive 0.1 ml of the intravenous vehicle solution without testcompound. After 5 minutes, the first blood samples (0.5 ml) are takenfrom the carotid artery and collected in standard microtainer tubescontaining ethylenediamine tetraacetic acid. Saline (0.5 ml) is injectedto flush the catheter and replace blood volume. Subsequent blood samplesare taken at two hours and four hours bag the same method. Blood samplesare mixed well and kept on ice until the completion of the experiment.Plasma is obtained by centrifugation of the blood samples at 40° C. Theplasma (50 μl) is treated with 5 μl of precipitating reagent (dextransulfate, 10 g/l; 0.5 M magnesium chloride) to remove VLDL/LDL. Aftercentrifugation, the resulting supernatant (25 μl) containing the HDL isanalyzed for radioactivity using a liquid scintillation counter.

The percentage [³H]CE transferred from HDL to LDL and VLDL (% transfer)is calculated based on the total radioactivity in equivalent plasmasamples before precipitation. Typically, the amount of transfer from HDLto LDL and VLDL in control animals is 20% to 35% after 4 hours.

Alternatively, conscious, non-anesthetized animals can receive an oralgavage dose of test compound as a suspension in 0.1% methyl cellulose inwater. At a time determined for each compound at which plasma levels ofthe test substance reach their peak (C_(max)) after oral dosing, theanimals are anesthetized with pentobarbital and then dosed with 0.2 mlof a solution containing [³H]CE-HDL into the jugular vein as describedabove. Control animals receive 0.25 ml of the vehicle solution withouttest compound by oral gavage. After 4 hours, the animals are sacrificed,blood samples are collected, and the percentage [³H]CE transferred fromHDL to LDL and VLDL (% transfer) is assayed as described above.

Alternatively, inhibition of CETP activity by a test compound can bedetermined by administering the compound to mice that have been selectedfor expression of human CETP (hCETP) by transgenic manipulation (hCETPmice). Test compounds can be administered by intravenous injection, ororal gavage and the amount of transfer of tritium-labeled cholesterylester ([³H]CE) from HDL to VLDL and LDL particles is determined, andcompared to the amount of transfer observed in control animals. C57Bl/6mice that are homozygous for the hCETP gene are maintained on a high fatchow diet, such as TD 88051, as described by Nishina et al. (J LipidRes., 31, 859-869 (1990)) for at least two weeks prior to the study.Mice receive an oral gavage dose of test compound as a suspension in0.1% methyl cellulose in water or an intravenous bolus injection of testcompound in 10% ethanol and 90% polyethylene glycol. Control animalsreceive the vehicle solution without test compound by oral gavage or byan intravenous bolus injection. At the start of the experiment allanimals receive 0.05 ml of a solution containing [³H]CE-HDL into thetail vein. [³H]CE-HDL is a preparation of human HDL containingtritium-labeled cholesterol ester, and is prepared according to themethod of Glenn et al. (Meth. Enzymol., 263, 339-351 (1996)). After 30minutes, the animals are exsanguinated and blood collected in standardmicrotainer tubes containing ethylenediamine tetraacetic acid. Bloodsamples are mixed well and kept on ice until the completion of theexperiment. Plasma is obtained by centrifugation of the blood samples at40° C. The plasma is separated and analyzed by gel filtrationchromatography and the relative proportion of [³H]CE in the VLDL, LDLand HDL regions is determined.

The percentage [³H]CE transferred from HDL to LDL and VLDL (% transfer)is calculated based on the total radioactivity in equivalent plasmasamples before precipitation. Typically, the amount of transfer from HDLto LDL and VLDL in control animals is 20% to 35% after 30 min.

Intestinal Cholesterol Absorption Assay

A variety of compounds are shown to inhibit cholesterol absorption fromthe intestinal tract. These compounds lower serum cholesterol levels byreducing intestinal absorption of cholesterol from both exogenoussources (dietary cholesterol) and endogenous cholesterol (secreted bythe gall bladder into the intestinal tract).

In hamsters the use of a dual-isotope plasma ratio method to measureintestinal cholesterol absorption has been refined and evaluated asdescribed by Turley et al. (J. Lipid Res. 35, 329-339 (1994), hereinincorporated by reference).

Male hamsters weighing 80-100 g are given food and water ad libitum in aroom with 12 hour alternating periods of light and dark. Four hours intothe light period, each hamster is administered first an intravenous doseof 2.5 μCi of [1,2-³H]cholesterol suspended in Intralipid (20%) and thenan oral dose of [4-¹⁴C]cholesterol in an oil of medium chaintriglycerides (MCT). The i.v. dose is given by injecting a 0.4 ml volumeof the Intralipid mixture into the distal femoral vein. The oral dose isgiven by gavaging a 0.6 ml volume of the MCT oil mixture introducedintragastrically via a polyethylene tube. After 72 hours the hamstersare bled and the amount of ³H and ¹⁴C in the plasma and in the originalamount of label administered are determined by liquid scintillationspectrometry. The cholesterol absorption will be calculated based on thefollowing equation:${{Percent}\quad {cholesterol}\quad {absorbed}} = {\frac{\% \quad {of}\quad {oral}\quad {dose}\quad {per}\quad {ml}\quad {of}\quad 72\quad {hour}\quad {plasma}\quad {sample}}{\% \quad {of}\quad {i.v.\quad {dose}}\quad {per}\quad {ml}\quad {of}\quad 72\quad {hour}\quad {plasma}\quad {sample}} \times 100}$

The examples herein can be performed by substituting the generically orspecifically described therapeutic compounds or inert ingredients forthose used in the preceding examples.

The invention being thus described, it is apparent that the same can bevaried in many ways. Such variations are not to be regarded as adeparture from the spirit and scope of the present invention, and allsuch modifications and equivalents as would be obvious to one skilled inthe art are intended to be included within the scope of the followingclaims.

What is claimed is:
 1. A therapeutic combination comprising a firstamount of an ileal bile acid transport (IBAT) inhibiting compound and asecond amount of a cholesteryl ester transfer protein (CETP) inhibitingcompound wherein the first amount and the second amount togethercomprise an anti-hyperlipidemic condition effective amount, ananti-atherosclerotic condition effective amount, or ananti-hypercholesterolemic condition effective amount of the compounds,and wherein said cholesteryl ester transfer protein inhibiting compoundcomprises compound C-12 represented by:

or enantiomers or racemates thereof.
 2. A therapeutic combinationcomprising a first amount of an ileal bile acid transport (IBAT)inhibiting compound and a second amount of a cholesteryl ester transferprotein (CETP) inhibiting compound wherein the first amount and thesecond amount together comprise an anti-hyperlipidemic conditioneffective amount, an anti-atherosclerotic condition effective amount, oran anti-hypercholesterolemic condition effective amount of thecompounds, wherein said cholesteryl ester transfer protein inhibitingcompound comprises compound C-12 represented by:

or enantiomers or racemates thereof, and wherein said ileal bile acidtransport inhibiting compound comprises compound B-5 represented by:

or enantiomers or racemates thereof.
 3. The therapeutic combination ofclaim 1, wherein said ileal bile acid transport inhibiting compoundcomprises compound B-5 represented by:


4. The therapeutic combination of claim 1, wherein said cholesterylester transfer protein inhibiting compound comprises compound C-12represented by:


5. The therapeutic combination of claim 4, wherein said ideal bile acidtransport inhibiting compound comprises compound B-5 represented by:


6. A method for the prophylaxis or treatment of a hyperlipidemiccondition comprising administering to a patient in need thereof acombination in unit dosage form wherein the combination comprises afirst amount of an ileal bile acid transport inhibiting compound and asecond amount of a cholesteryl ester transfer protein inhibitingcompound wherein the first amount and the second amount togethercomprise an anti-hyperlipidemic condition effective amount of thecompounds, and wherein said cholesteryl ester transfer proteininhibiting compound is represented by formula (C-12):

or enantiomers or racemates thereof.
 7. A method for the prophylaxis ortreatment of an atherosclerotic condition comprising administering to apatient in need thereof a combination in unit dosage form wherein thecombination comprises a first amount of an ileal bile acid transportinhibiting compound and a second amount of a cholesteryl ester transferprotein inhibiting compound wherein the first amount and the secondamount together comprise an anti-atherosclerotic condition effectiveamount of the compounds, and wherein said cholesteryl ester transferprotein inhibiting compound is represented by formula (C-12):

or enantiomers or racemates thereof.
 8. A method for the prophylaxis ortreatment of hypercholesterolemia comprising administering to a patientin need thereof a combination in unit dosage form wherein thecombination comprises a first amount of an ileal bile acid transportinhibiting compound and a second amount of a cholesteryl ester transferprotein inhibiting compound wherein the first amount and the secondamount together comprise an anti-hypercholesterolemic conditioneffective amount of the compounds, and wherein said cholesteryl estertransfer protein inhibiting compound is represented by formula (C-12):

or enantiomers or racemates thereof.